Finance

Lists
DSKYF:OTCMKTS
Daiichi Sankyo Co Ltd
16,16 $
+0,75%
(+0,12) 1D
14 հոկ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DSKYF...
Open
16,16 $
High
16,16 $
Low
16,16 $
Mkt. cap
30,89 մլրդ
Avg. vol.
3,48 հզր
Volume
202,00
52-wk high
29,10 $
52-wk low
13,85 $
Beta
-1,13
Shares outstanding
1,86 մլրդ
No. of employees
20 հզր
Open
16,16 $
High
16,16 $
Low
16,16 $
Mkt. cap
30,89 մլրդ
Avg. vol.
3,48 հզր
Volume
202,00
52-wk high
29,10 $
52-wk low
13,85 $
Beta
-1,13
Shares outstanding
1,86 մլրդ
No. of employees
20 հզր
News stories
From web sources and news partners
Profile
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent. Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey. Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
About Daiichi Sankyo Co Ltd
CEOHiroyuki Okuzawa
Employees20,2 հզր
Founded28 սեպ, 2005 թ.
HeadquartersԹյուո, Տոկիո, Ճապոնիա
Sector-
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
500,76 մլրդ
558,11 մլրդ
589,59 մլրդ
574,74 մլրդ
Cost of goods sold
155,98 մլրդ
118,28 մլրդ
302,44 մլրդ
124,29 մլրդ
Cost of revenue
155,98 մլրդ
118,28 մլրդ
302,44 մլրդ
124,29 մլրդ
Research and development expenses
111,72 մլրդ
122,11 մլրդ
126,23 մլրդ
115,46 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
189,08 մլրդ
228,23 մլրդ
154,06 մլրդ
249,96 մլրդ
Operating expense
297,25 մլրդ
350,29 մլրդ
279,38 մլրդ
365,35 մլրդ
Total operating expenses
453,23 մլրդ
468,57 մլրդ
581,82 մլրդ
489,64 մլրդ
Operating income
47,52 մլրդ
89,54 մլրդ
7,77 մլրդ
85,10 մլրդ
Other non operating income
-
-
6,22 մլրդ
-2,00 մլն
EBT including unusual items
57,78 մլրդ
106,73 մլրդ
22,44 մլրդ
91,34 մլրդ
EBT excluding unusual items
57,78 մլրդ
106,73 մլրդ
7,84 մլրդ
91,34 մլրդ
Income tax expense
12,46 մլրդ
20,10 մլրդ
-39,84 մլրդ
22,70 մլրդ
Effective tax rate
21,57%
18,83%
-177,52%
24,86%
Other operating expenses
-3,56 մլրդ
-49,00 մլն
-908,00 մլն
-69,00 մլն
Net income
45,31 մլրդ
86,63 մլրդ
62,28 մլրդ
68,64 մլրդ
Net profit margin
9,05%
15,52%
10,56%
11,94%
Earnings per share
-
-
-
-
Interest and investment income
10,68 մլրդ
19,08 մլրդ
377,00 մլն
9,74 մլրդ
Interest expense
-834,00 մլն
-2,16 մլրդ
-18,91 մլրդ
-3,23 մլրդ
Net interest expenses
9,84 մլրդ
16,91 մլրդ
-18,53 մլրդ
6,51 մլրդ
Depreciation and amortization charges
-
-
-
-
EBITDA
66,41 մլրդ
109,18 մլրդ
28,89 մլրդ
106,58 մլրդ
Gain or loss from assets sale
1,75 մլրդ
573,00 մլն
8,50 մլրդ
180,00 մլն
AI content may include mistakes. Learn more
Google Apps